Entering text into the input field will update the search result below

Cerus Corporation (CERS) CEO Obi Greenman on Q1 2020 Results - Earnings Call Transcript

May 05, 2020 10:56 PM ETCerus Corporation (CERS) Stock2 Comments
SA Transcripts profile picture
SA Transcripts

Cerus Corporation (NASDAQ:CERS) Q1 2020 Earnings Conference Call April 5, 2020 4:30 PM ET

Company Participants

Tim Lee - Investor Relations

Obi Greenman - President and Chief Executive Officer

Kevin Green - Chief Financial Officer

Vivek Jayaraman - Chief Operating Officer

Carol Moore - SVP of Regulatory Affairs and Quality

Conference Call Participants

Mathew Blackman - Stifel

Josh Jennings - Cowen and Company, LLC

Jacob Johnson - Stephens Inc.


Ladies and gentlemen, thank you for standing by and welcome to the Cerus Corporation Q1 2020 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there'll be a question-and-answer session. [Operator Instruction] Please be advised that today's conference is being recorded.

It is now my pleasure to turn the call over to your host Mr. Tim Lee. Please go ahead.

Tim Lee

Thank you, operator, and good afternoon. I'd like to thank everyone for joining us today. With me on the call are Obi Greenman, Cerus' President and Chief Executive Officer; Kevin Green, Cerus' Chief Financial Officer; Vivek Jayaraman, our Chief Operating Officer; Dr. Laurence Corash, our Chief Scientific Officer; and Carol Moore, our Senior Vice President of Regulatory Affairs and Quality.

Cerus issued a press release today announcing our financial results for the first quarter ended March 31, 2020 and also describing the Company's recent business highlights. You can access a copy of this announcement on the Company website at www.cerus.com. I like to remind you that some of the statements we will make on this call related to future event and performance, rather than historical facts and are forward-looking statements.

Examples of forward-looking include those related to our future financial and operating results and including our 2020 financial guidance and goals, operating expenses and gross margins, commercial development efforts, future growth and growth

Recommended For You

Comments (2)

World-class team! I have been in the stock for 10+ years and will continue to be patient. There is no doubt in my mind that Intercept will become the standard of care for blood safety. Thank you, Obi and team.
@Timothy Blackbread

As millions throughout the globe are getting infected, protecting the safety of blood for transfusion becomes essential especially considering many cities are likely going to suffer from blood shortage. Buy CERS while you can before this one surges.
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About CERS

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on CERS

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.